DAX®13.248,05-0,49%TecDAX®3.089,33-0,17%S&P 500 I3.668,86-0,03%Nasdaq 10012.456,41+0,01%
finanztreff.de

BUSINESS WIRE: Vertex and Republic of Ireland Expand Long-Term Cystic Fibrosis Medicines Reimbursement Agreement to Include Triple Combination Therapy for All Eligible Patients Ages 12 and Over Once Licensed

| Quelle: Business_Wire | Lesedauer etwa 4 min. | Text vorlesen Stop Pause Fortsetzen

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

LONDON (BUSINESS WIRE) 13.12.2019

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirmed that, following recent collaborative discussions, it has negotiated an agreement with the Health Service Executive (HSE) in the Republic of Ireland to expand the existing long-term cystic fibrosis (CF) reimbursement agreement to include the triple combination regimen (elexacaftor, tezacaftor and ivacaftor), which is under review and pending approval by the European Medicines Agency, for all eligible patients ages 12 and older in line with the potential future licensed indication.

This expands the existing agreement which had already included access to current and future Vertex medicines for people in Ireland with CF of any age who:

  • Have one of the specified mutations as included in the KALYDECO® marketing authorization (G551D, G551S, S549R, G1244E, S1251N, G1349D, S1255P, G178R or S549N) or
  • Are homozygous for the F508del mutation or
  • Are heterozygous for the F508del mutation and have a specified mutation (P67L, D579G, D1152H, R117C, 711+3A→G, 2789+5G→A, L206W, S945L, 3272-26A→G, R352Q, S977F, 3849+10kbC→T, A455E or R1070W) and people ages 18 and older and have an R117H mutation.

This innovative long-term agreement also enabled rapid access for people with these mutations if the labels of the existing medicines were expanded to cover additional age groups and if new Vertex medicines were approved for these populations.

Ludovic Fenaux, Senior Vice President, Vertex International, said, “With this expanded agreement, even more patients in the Republic of Ireland will be among the first in Europe to benefit from the triple combination treatment once the medicine is licensed.”

Triple combination treatment (elexacaftor, tezacaftor and ivacaftor) is not currently licensed for use in the European Union. Vertex submitted a Marketing Authorization Application to the European Medicines Agency on October 31, 2019.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has four approved medicines in the U.S. and three approved medicines in Europe that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency, and APOL1-mediated kidney disease. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London, UK. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 10 consecutive years on Science magazine's Top Employers list and top five on the 2019 Best Employers for Diversity list by Forbes.

Special Note Regarding Forward-looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, the statements by Mr. Fenaux in the second paragraph of this press release and statements regarding the expansion of the existing long-term cystic fibrosis reimbursement agreement and Vertex’s Marketing Authorization Application submission to the European Medicines Agency. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons, obtaining approval and commercializing elexacaftor, tezacaftor and ivacaftor in Europe, developing additional medicines to treat cystic fibrosis, and other risks listed under Risk Factors in Vertex's annual report and subsequent quarterly reports filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

Vertex Pharmaceuticals Incorporated
UK/Irish Media: +44 20 3204 5275
MediaInfo@vrtx.com

Investors: 617-961-7163
InvestorInfo@vrtx.com

Werbung

Das könnte Sie auch interessieren

Weitere Nachrichten

Quelle: Business_Wire
14:05 BUSINESS WIRE: Telefonica UK (O2) e IDEMIA collaborano per dotare di contatori intelligenti 23 milioni di utenze domestiche britanniche, entro il 2025 e in tutta sicurezza
14:00 BUSINESS WIRE: Dawex Data Exchange Platform Matches European Data Governance Act Criteria
13:47 BUSINESS WIRE: ESI trägt zum Durchbruch von Nissan bei der Produktion von Carbonfaserteilen für sicherere und leichtere Fahrzeuge bei
13:06 BUSINESS WIRE: LivaNova e Gyrus Capital stipulano un accordo per l'acquisto del business delle valvole cardiache LivaNova 43,80 +2,82%
12:00 BUSINESS WIRE: M7 Group entscheidet sich für Hansen Customer Care and Billing, um Abrechnungsprozesse ins digitale Zeitalter zu bringen
12:00 BUSINESS WIRE: M7 Group sceglie Hansen Customer Care and Billing per dirigere le operazioni di fatturazione nell’era digitale
11:22 BUSINESS WIRE: Der SuperGaN Gen V FET von Transphorm bietet den weltweit niedrigsten ON-Widerstand und zielt auf Anwendungen für Elektrofahrzeuge
11:00 BUSINESS WIRE: ESI contribuisce al progresso di Nissan nella produzione di parti con aggiunta di fibra di carbonio, per veicoli più sicuri e leggeri
10:38 BUSINESS WIRE: Velodyne Lidars Velabit™ gewinnt den prestigeträchtigen Best of What's New Award von Popular Science
09:22 BUSINESS WIRE: Wipro versorgt Verifone Inc. mit agilen technischen Kundendienstleistungen
Rubrik: Finanzmarkt
14:11 ROUNDUP: Italien schränkt Reisen über Weihnachten stark ein
14:06 Verärgerung bei Gewerkschaft über Umzugspläne von Stena Line
14:06 IRW-News: International Consolidated Uranium Inc. : Berufung von Leigh Curyer in das Advisory Board und von John Jentz in das Board of Directors von International Consolidated Uranium INTL CONSOL.URANIUM INC. 0,378 -5,500%
14:06 IRW-News: Havn Life Sciences Inc.: Havn Life Sciences schließt eine Partnerschaft mit dem Westwood Institute, einer gemeinnützigen Organisation, die sich für die psychische Gesundheit von Kriegsveteranen einsetzt HAVN LIFE SCIENCES INC. 0,522 +4,400%
14:05 IRW-News: Desert Gold Ventures Inc. : Desert Gold startet Explorationsprogramm in seinem Projekt SMSZ in West-Mali; geplant sind Bohrungen über 20.000 Meter und bei Bedarf zusätzliche Bohrungen über 20.000 Meter DESERT GOLD VENTURES 0,086 -4,444%
14:04 Zweite Welle: Ansturm in heimischen Bergen erwartet
14:02 DGAP-DD: EXASOL AG (deutsch) EXASOL AG NA O.N. 22,60 +0,44%
14:02 IRW-News: Chemesis International Inc.: Chemesis International Inc. schließt Markenpartnerschaft mit Ubican Global CHEMESIS INTL INC. O.N. 0,346 +5,488%
14:02 IRW-News: Cypress Development Corp.: Cypress Development untersucht Chloridlaugung für Lithiumprojekt Clayton Valley in Nevada Cypress Development 0,404 +9,189%
14:00 BUSINESS WIRE: Dawex Data Exchange Platform Matches European Data Governance Act Criteria

News-Suche

Suchbegriff:

Aktuelle Videos

HSBC Trading TV

Werbung

Trading-Tipp

Börsen & Märkte

US-Marktüberblick

zur Mediathek
Werbung

Werbung
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Wie hat sich Ihr Wertpapierdepot seit Jahresbeginn entwickelt?
Jetzt abstimmen!
Alle Umfragen ansehen